Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-AT Open-Label Extension in Children With Autism
NCT02649959Phase 3Active, not recruiting
- Sponsor
- Curemark
- Start
- Oct 2015
- Primary completion
- Jan 2028
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of CM-AT in Autism Spectrum Disorder (ASD), sponsored by Curemark. Started Oct 2015; status: active, not recruiting.
02
Drugs
CM-AT
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02649959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649959.